Behavior of CD44 Receptors in Mammary Tumors of Dogs

DOI: 10.4236/ojvm.2012.22008   PDF   HTML     4,494 Downloads   7,797 Views   Citations

Abstract

CD44 is a cell adhesion molecule closely related to tumor progression in humans. In canine mammary tumors, little information is available about this molecule. The aim of this study was to analyze, by immunohistochemistry, the behavior of this molecule in canine mammary tumors with or without the presence of metastasis. The dogs were divided in groups without metastasis (G1) and with metastasis (G2, with subsets A—original neoplasia and B—metastatic neoplasia). Tumors were classified according to the World Health Organization (WHO) criteria. The cells were counted whereby the plasma membrane and/or cytoplasm are stained. There was a significant increase in the number of cells immunostained for CD44 in the metastastic masses (G2B) as compared to groups G1 and G2A. It is concluded that in metastatic mass there was a significant increase in CD44 receptors, probably important for biology of the mammary tumor of dogs.

Share and Cite:

G. Magalhães, A. Silveira, D. Munari and A. Alessi, "Behavior of CD44 Receptors in Mammary Tumors of Dogs," Open Journal of Veterinary Medicine, Vol. 2 No. 2, 2012, pp. 48-51. doi: 10.4236/ojvm.2012.22008.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] M. Gotte and G. W. Yip, “Heparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective,” Cancer Research, Vol. 66, No. 21, 2006, pp. 10233-10237. doi:10.1158/0008-5472.CAN-06-1464
[2] D. Naor, R. V. Sionov and D. Ish-shalom, “CD44: Structure, Function, and Association with the Malignant Process,” Advances in Cancer Research, Vol. 71, 1997, pp. 241-319. doi:10.1016/S0065-230X(08)60101-3
[3] S. B. Wallach-Dayan, A. M. Rubinstein, C. Hand, R. Breuer and D. Naor, “DNA Vaccination with CD44 Variant Isoform Reduces Mammary Tumor Local Growth and Lung Metastasis,” Molecular Cancer Therapeutics, Vol. 7, 2008, pp. 1615-1623. doi:10.1158/1535-7163.MCT-07-2383
[4] K. Friedrichs, F. Franke, B. W. Lisboa, G. Kügler, I. Gille, H. J. Terpe, F. Holzel, H. Maass and U. Günthert, “CD44 Isoforms Correlate with Cellular Differentiation but not with prognosis in Human Breast Cancer,” Cancer Research, Vol. 55, 1995, pp. 5424-5433.
[5] L. Hebbard, A. Steffen, V. Zawadzki, C. Fieber, N. Howells, J. Moll, H. Ponta, M. Hofmann and J. Sleeman, “CD44 Expression and Regulation during Mammary Gland Development and Function,” Journal of Cell Science, Vol. 113, 2000, pp. 2619-2630.
[6] J. C. Harrell, W. W. Dye, D. C. Allred, P. Jedlicka, N. S. Spoelstra, C. A. Sartorius and K. B. Horwitz, “Estrogen Receptor Positive Breast Cancer Metastasis: Altered Hormonal Sensitivity and Tumor Aggressiveness in Lymphatic Vessels and Lymph Nodes,” Cancer Research, Vol. 66, No. 18, 2006.
[7] G. R Rutteman, S. J. Withrow and E. G Macewen, “Tumors of the Mammary Gland,” In: S. J. Withrow and E. G. Macewen, Eds., Small Animal Clinical Oncology, 3rd Edition, W. B. Saunders, Philadelphia, 2001, pp. 455-477.
[8] J. Madrazo, R. A. Garcia-Fernandez, M. J. Garcia-Iglesias, A. J Duran, J. Espinosa and C. Perez-Martinez, “The Role of CD44 Adhesion Factor in Canine Mammary Carcinomas,” The Veterinary Journal, Vol. 180, No. 3, 2009, pp. 371-376. doi:10.1016/j.tvjl.2008.01.007
[9] V. Paltian, S. Alldinger, W. Baumgartner and P. Wohlsein, “Expression of CD44 in Canine Mammary Tumours,” Journal of Comparative Pathology, Vol. 141, No. 4, 2009, pp. 237-247. doi:10.1016/j.jcpa.2009.05.007
[10] H. Misdorp, R. Else and E. Hellman, “Histologic Classification of Mammary Tumors of the Dog and Cat,” In: World Health Organization International Histological Classification of Tumors of Domestic Animals, Series 2, Vol. 7, No. 2, Armed Forces Institute of Pathology, Washington DC, 1999.
[11] S. M. Hsu, L. Raine and H. A. Fanger, “A Comparative study of Peroxidase-Antiperoxidase Method and an Avidin Biotin Complex Method for Studying Polypeptide Hormones with Radioimmunuoassay Antibodies,” American Journal of Clinical Pathology, Vol. 75, 1981, pp. 734-738.
[12] C. W. Elston and I. O. Ellis, “Pathological Prognostic Factors in Breast Cancer, I. The Value of Histological Grade in Breast Cancer: Experience from Large Study with Long Term Follow-Up,” Histopathology, Vol. 19, No. 5, 1991, pp. 403-410. doi:10.1111/j.1365-2559.1991.tb00229.x
[13] J. F. Hampe and W. Misdorp, “Tumours and Dysplasias of the Mammary Gland,” Bulletim of World Health Organization, Vol. 50, 1974, pp. 111-133.
[14] O. Pozdnyakova, M. M. Hoang, K. A. Dresser and M. Mahalingam, “Prognostic Value of E-cadherin, Beta-catenin, CD44v6, and HER2/neu in Metastatic Cutaneous Adenocarcinoma,” Archives of Pathology and Laboratory Medicine, Vol. 133, No. 8, 2009, pp. 1285-1290.
[15] Y. Xin, A. Grace, M. M. Gallagher, B. T. Curran, M. B. Leader and E. W. Kay, “CD44V6 in Gastric Carcinoma: A Marker of Tumor Progression,” Applied Immunohistochemistry Molecular Morphology, Vol. 9, No. 2, 2001, pp. 138-142. doi:10.1097/00022744-200106000-00006
[16] S. Mine, T. Fujisaki, C. Kawahara, T.Tabata, T. Iida, M. Yasuda, T. Moneda and Y. Tanaka, “Hepatocyte Growth Factor Enhances Adhesion of Breast Cancer Cells to Endothelial Cells in Vitro through Up-Regulation of CD44,” Experimental Cell Research, Vol. 288, No. 1, 2003, pp. 189-197. doi:10.1016/S0014-4827(03)00184-8

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.